News & Updates
Filter by Specialty:

X-TOLE OLE interim analysis shows long-term efficacy of novel agent for focal epilepsy
10 Apr 2025
byAudrey Abella
Interim data from the ongoing 7-year open-label extension (OLE) of the phase IIb X-TOLE study reflect the long-term efficacy and safety of azetukalner, an investigational, potent Kv7 potassium channel opener, for the treatment of adults with focal epilepsy.